Risdiplam (EVRYSDI®) is an oral survival of motor neuron 2 (SMN2) pre-mRNA splicing modifier approved by the EMA and MHRA for the treatment of patients aged ≥2 months with Types 1–3 spinal muscular atrophy (SMA) or 1–4 SMN2 copies. JEWELFISH (NCT03032172) is an open-label study of risdiplam in 174 patients with SMA who previously received RG7800 (RO6885247), nusinersen (SPINRAZA®), olesoxime or onasemnogene abeparvovec (ZOLGENSMA®). JEWELFISH assesses the safety, tolerability and pharmacokinetics/pharmacodynamics of risdiplam in a broad range of ages (1–60 years), SMA types (1–3), SMN2 copy numbers (1–4) and motor functions (non-sitters/sitters/walkers). Thirteen patients previously received RG7800, 76 received nusinersen, 70 received olesoxime and 14 received onasemnogene abeparvovec; one patient withdrew at baseline. Risdiplam led to a >2-fold increase in SMN protein within 4 weeks versus baseline, irrespective of previous treatment. No drug-re- lated safety findings led to withdrawal in any patients. The safety profile of risdiplam was consistent with observations in the FIREFISH (NCT02913482) and SUNFISH (NCT02908685) studies. Exploratory analyses demonstrated overall stabilisation of motor function following 24-month risdiplam treatment in patients aged 2–60 years as assessed by the 32-item Motor Function Measure and Revised Upper Limb Module (data-cut: 31 January 2022).